Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19777716 | 0.86 | DRD1 (0.39) | — | |
| SCHEMBL19519797 | 0.86 | MCHR1 (0.34) | — | |
| SCHEMBL19519685 | 0.83 | — | — | |
| SCHEMBL5019529 | 0.83 | POLB (0.32) | — | |
| SCHEMBL19702867 | 0.83 | — | — | |
| SCHEMBL17796122 | 0.83 | PSMB11 (0.34) | HTT | |
| SCHEMBL17796083 | 0.82 | ALDH1A1 (0.33) | HTT | |
| SCHEMBL17796091 | 0.82 | ALDH1A1 (0.33) | HTT | |
| SCHEMBL17796071 | 0.82 | ALDH1A1 (0.33) | HTT | |
| SCHEMBL17796072 | 0.82 | ALDH1A1 (0.33) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308668-B2 | Tricyclic benzoxaborole compounds and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-04 | — | — | US | disclosed |
| US-20180044355-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-20180016285-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, LLC | 2018-01-18 | — | — | US | disclosed |
| US-9796735-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044355-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | CBX2, BRD4, BRD3 | HTT 2986/4885 |
| US-20180016285-A1 | Boron-Containing Small Molecules | BCL6B, BLVRB, BCL6 | HTT 4176/4885 |
| US-10308668-B2 | Tricyclic benzoxaborole compounds and uses thereof | CBX2, BRD4, BRD3 | HTT 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.